C
셀레스트라
352770KOSDAQ의료용품 및 기타 의약 관련제품 제조업50.5 / 100
Reference Date: 2026-06-10
Financial Score26.0 / 40
News Sentiment7.5 / 25
Momentum10.0 / 20
Disclosure7.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Roughly flat over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Celestera develops and commercializes services for early disease diagnosis using genome-based biohealth information processing, liquid biopsy platforms, cancer diagnostics, and multi-omics technologies. Key products include Geno-Test, CD-Prime, and Cancer-Prime, with a dedicated bio big data center for research and commercialization.
Number of Employees
11people
Average Salary
85.7M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 19.194.0Point
PBR
—Industry Average 1.303.5Point
ROE
3157.50Industry Average -4.893.5Point
Well below industry avg
Debt Ratio
-10.65Industry Average 6.868.0Point
Half of industry avg (excellent)
Trend 2023~20257.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼50.9% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲45.0% (2-year basis)
ROE Trend
4.0 / 4
Avg ROE 951.3% (improving, 3yr)
Detailed News Sentiment
1 totalPositive 0Neutral 0Negative 1Average Sentiment Score 30
- Negative셀레스트라, 분기 매출 2408만원…상장적격성 실질심사 사유 발생
셀레스트라는 분기 매출이 상장 기준 미달로 인해 영업 정지 가능성이 제기되어 부정적 영향을 받고 있다.
Detailed Momentum
52-week position4.0Point
52w mid range (50%)
Current 5,250Won52-week high 5,25052-week low 5,250
1-month return3.0Point
1m 0% (flat)
Volume trend3.0Point
Volume flat
Detailed Disclosure
12 totalPositive 0Neutral 11Negative 1
- Neutral기타경영사항(자율공시) (상장폐지결정등 효력정지 가처분 신청)2026-06-09
- Neutral기타시장안내 (정리매매 보류 관련)2026-06-09
- Neutral주권매매거래정지 (투자자 보호)2026-06-09
- Neutral주권매매거래정지해제 (상장폐지에 따른 정리매매 개시)2026-06-08
- Neutral기타시장안내 (기업심사위원회 심의·의결 결과 안내)2026-06-08